The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy

[1] Karim AM(2023)Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies Biochem Pharmacol 212 115545-173

[2] Eun Kwon J(2016)Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer J Cancer 7 167-1432

[3] Ali T(2021)Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a north indian tertiary care center Ann Surg Oncol 29 1423-2405

[4] Jang J(2018)Association between BRCA status and triple-negative breast cancer: a meta-analysis Front Pharmacol 21 909-516

[5] Ullah I(2021)Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer N Engl J Med 384 2394-637

[6] Lee YG(2016)Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations Breast Cancer Res Treat 157 511-1508

[7] Park DW(2022)molecular characterization by the 21-gene breast cancer (BC) recurrence score (RS) test of BRCA1/2 mutation carriers (MBRCA1/2) versus the general BC patient (PT) population Ann Oncol 33 152p-748

[8] Qiu J(2018)Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT trial Nat Med 24 628-21

[9] Xue X(2018)Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Ann Oncol 29 1497-146

[10] Hu C(2020)Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial JAMA Oncol 6 744-172

[1] Karim AM(2023)Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies Biochem Pharmacol 212 115545-173

[2] Eun Kwon J(2016)Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer J Cancer 7 167-1432

[3] Ali T(2021)Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a north indian tertiary care center Ann Surg Oncol 29 1423-2405

[4] Jang J(2018)Association between BRCA status and triple-negative breast cancer: a meta-analysis Front Pharmacol 21 909-516

[5] Ullah I(2021)Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer N Engl J Med 384 2394-637

[6] Lee YG(2016)Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations Breast Cancer Res Treat 157 511-1508

[7] Park DW(2022)molecular characterization by the 21-gene breast cancer (BC) recurrence score (RS) test of BRCA1/2 mutation carriers (MBRCA1/2) versus the general BC patient (PT) population Ann Oncol 33 152p-748

[8] Qiu J(2018)Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT trial Nat Med 24 628-21

[9] Xue X(2018)Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Ann Oncol 29 1497-146

[10] Hu C(2020)Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial JAMA Oncol 6 744-172